Neuroprotection & Alzheimer's diseases - Allinky Biopharma

Neuroprotection and Alzheimer’s disease
The study of brain function and disease during ageing or in the event of an acute injury are one of the most challenging works for scientists and physicians. Little progress has been achieved in the development of drugs to preserve neuronal integrity and function. Nowadays the field of brain and CNS (central nervous system) holds the embarrassing top one of unmet medical needs with the highest failure of experimental drugs in clinical trials. Despite decades of clinical research, there is little evidence of positive effects of current treatments for Alzheimer's disease. Novel approaches beyond current treatments of disease modifiers are needed. In this regard, Allinky in close collaboration with neurophysiologists is working to identify the molecular insights of neuronal death in Alzheimer’s disease. The Founders of Allinky have demonstrated that non-neuronal cells in the brain such as astrocytes and microglia cells might unexpectedly contribute significantly to neuronal death under a chronic inflammatory and oxidative stress condition. These non-neuronal cells in the brain might foster the amilogenic processing of APP; the resistance to neuronal progression signals such as IGF-1; and the over expression of certain MAP kinases responsible for neuron death. Allinky is currently developing allosteric inhibitors of JNK MAP Kinases for the treatment of Alzheimer's Disease. These novel compounds decrease beta-amyloid production as well as restore insulin and IGF-1 intracelullar signals under chronic inflammatory conditions and thus contribute to neuron survival and progression. These innovative compounds represent a new approach for the treatment of brain diseases.